Corporate Transformation of Cybin Inc. into Helus Pharma
Exchange and Listing Changes
On 3 January 2026 Cybin Inc. filed Form 25 with the U.S. Securities and Exchange Commission to terminate its listing on the NYSE MKT. The filing initiated the company’s transition to the Nasdaq Global Market. Beginning 5 January 2026, the company will trade under the new ticker symbol HELP on Nasdaq. Simultaneously, the company’s Canadian listing will adopt the same ticker. The change reflects the company’s shift from a specialist in psychedelic‑drug research to a broader biopharmaceutical entity.
Rebranding and Corporate Identity
The filing was accompanied by an official name change to Helus Pharma. The new name and branding signal a strategic pivot from a narrow focus on psychedelic compounds to a wider clinical research agenda across mental‑health therapeutics. The rebranding is intended to align the company’s public image with its expanded product portfolio and to reinforce its status as a commercial‑stage pharmaceutical enterprise.
Product and Pipeline Highlights
Helus Pharma continues to develop a portfolio of novel serotonergic agonists (NSAs). The company’s pipeline remains centered on therapeutic agents for mood disorders, anxiety, PTSD, and substance‑use disorders. The shift to a broader biopharma focus is expected to diversify research efforts beyond psychedelic‑based compounds and to accelerate clinical development timelines.
Market Context
The announcement coincides with industry projections that the psychedelic‑drugs market will grow to USD 9.20 billion by 2033, with a compound annual growth rate of 12.1 % between 2025 and 2033. North America is projected to hold 45 % of the market share. Key competitors in the space include Compass Pathways, MindMed, Pfizer, Atai Life Sciences, and Jazz Pharmaceuticals. Helus Pharma’s reorientation positions it to compete within this expanding therapeutic landscape.
Financial Snapshot (as of 1 January 2026)
| Item | Value |
|---|---|
| Close price (2026‑01‑01) | USD 8.28 |
| 52‑week high (2025‑01‑06) | USD 10.73 |
| 52‑week low (2025‑04‑06) | USD 4.81 |
| Market capitalization | USD 413,425,088 |
| Price‑earnings ratio | -2.49 |
The company’s market capitalization and recent price movement illustrate the volatility associated with transitions in the biopharmaceutical sector. The forthcoming Nasdaq listing and rebranding are anticipated to influence investor perception and liquidity.
Outlook
Helus Pharma’s entry onto Nasdaq and its broader biopharmaceutical focus aim to enhance capital‑raising capabilities, increase regulatory engagement, and expand market reach. The company’s continued development of serotonergic agonists positions it to capture a share of the projected growth in mental‑health therapeutics. Investors and stakeholders will monitor the company’s clinical milestones, regulatory approvals, and market performance following the transition.
